Seer

Biotech & Life Sciences · Redwood City, United States · Founded 2017 · IPO 2020

Seer is a biotechnology company that has developed a platform for proteomics, the large-scale study of proteins. The company's flagship product, the Proteograph, is a platform that enables researchers to conduct deep, unbiased, and rapid analysis of the proteome. Seer's technology is designed to provide a more comprehensive view of the proteome than was previously possible. This is achieved through a combination of proprietary nanoparticles and software that allows for the selective capture and analysis of proteins from complex biological samples. The company's platform is used by researchers in a variety of fields, including drug discovery, diagnostics, and basic research. Seer's business model is based on the sale of its Proteograph platform, as well as recurring revenue from the sale of consumables and software. The company's customers include academic and government research institutions, as well as pharmaceutical and biotechnology companies. Seer is a publicly traded company, listed on the Nasdaq stock exchange under the ticker symbol SEER. Keywords: proteomics, biotechnology, Proteograph, life sciences, genomics, data analysis, drug discovery, research tools, biological insights, multi-omics

Revenue $10–50M

Headcount 100–500

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Investors

7 investors on Seer's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Maverick Ventures

Invus

Series B+ 5 investors entered at this stage

Wing Venture Capital

Aju IB Investment

aMoon Fund

Fidelity Investments

T. Rowe Price

Global footprint

Where Seer has talent and traffic

Workforce by country

11 countries with
team presence

🇺🇸 United States84.3%

🇩🇪 Germany3.9%

🇬🇧 United Kingdom2.9%

🇨🇦 Canada2%

🇳🇱 Netherlands1%

Top 5 of 11 shown

Web traffic by country

23K monthly visits
across markets

🇺🇸 United States60%

🇨🇦 Canada19.6%

🇬🇧 United Kingdom10.4%

🇮🇳 India8.3%

🇩🇪 Germany1.3%

Top 5 markets shown

Talent graph

The shape of Seer's talent

Dealroom maps Seer's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 standout operatorsDealroom-flagged across the org

7 AI specialistsincl. 3 core researchers

152 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Seer's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$33M patent portfolio · 39 active families

Estimated portfolio value

$33M

3.2× smaller than top peer NanoString Technologies ($106M)

39 active patent families

Where Seer innovates AssayBioinformaticsMolecular biologyBiochemistryBiological organism

Where Seer concentrates vs peers

Each axis is a top-10 topic across Seer and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Seer

An AI-synthesized read of the highest-engagement posts about Seer on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Seer on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles